Addex Therapeutics (ADXN) Corporate Presentation summary

Strategic partnerships and pipeline milestones

• 20% equity interest in Neurosterix, a spin-out advancing CNS pipeline with $65M Series A funding and multiple programs nearing clinical stages.

• GABAB PAM for substance use disorder partnered with Indivior, IND enabling studies completed, eligible for $330M in milestones and royalties.

• Dipraglurant for post-stroke/TBI recovery is Phase 2 ready, targeting neuroplasticity to aid rehabilitation.

• GABAB PAM for chronic cough ready to enter IND enabling studies, with strong preclinical efficacy and safety profile.

• M4 PAM for schizophrenia completed IND enabling studies, Phase 1 planned for H2 2025.

Clinical and preclinical program highlights

• Dipraglurant demonstrated significant functional recovery in preclinical stroke models and is safe/tolerable in Phase 1 and 2 studies.

• GABAB PAM for SUD and chronic cough shows improved efficacy and tolerability over baclofen, with no tolerance or major side effects in animal models.

• Compound A (GABAB PAM) matches or exceeds efficacy of current treatments for cough, with superior safety and no sedation or growth hormone elevation.

• Neurosterix pipeline includes M4 PAM for schizophrenia, mGlu7 NAM for mood disorders, and mGlu2 NAM for neurocognitive disorders, all advancing toward clinical trials.

• Multiple programs are supported by robust IP and are positioned for significant value inflection milestones.

Market opportunity and financial position

• Large unmet needs in post-stroke/TBI recovery, SUD, and chronic cough, with global stroke market at $37B and SUD burden in the US over $600B annually.

• Chronic cough affects 10% of the population, with current treatments often ineffective or poorly tolerated.

• Cash position of CHF 2.8M ($3.2M) as of March 31, 2025, with runway through 2026 and no debt.

• Dual listed on SIX Swiss Exchange and Nasdaq, with 128.26M shares outstanding and significant institutional and management ownership.

• Analyst coverage by HC Wainwright, with strong industry partnerships and a solid foundation for future growth.